Fig. 3: Top variables associated with IMI risk.
The top 25 biomarkers that passed external validation and ranked on how many internal validation splits the biomarker passed the replication criteria in the model adjusted for technical covariates in addition to the external validation are shown. Each predictor is represented by two rows, with the discovery result (blue) presented first and the validation result presented second (red). The results are sorted by predictor type (clinical, metabolite or protein) and effect size from the combined analysis of the discovery and validation samples. P value was calculated based on a 2 d.f. Wald test for metabolites analyzed using the missing indicator method (biomarker and missing indicator) and a 1 d.f. Wald test otherwise (biomarker only), two-sided in both cases. The 95% CI of the point estimate (log(HR)) was calculated for the biomarker only and might include 1 even if P < 0.05 from the 2 d.f. (biomarker + indicator) Wald test. aIL-6 and bKIM1 values were determined from multiple Olink panels and tested in separate statistical tests. n = 296 cases and 1,121 noncases in the discovery sample; n = 124 cases and 477 noncases in the validation sample.
